Posted by Michael Wonder on 09 Aug 2021
Barriers to US biosimilar market growth: lessons from biosimilar patent litigation
6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system.
The Biologics Price Competition and Innovation Act, passed in 2010 as part of the Affordable Care Act, created an abbreviated approval pathway for biosimilars—versions of “originator” biologic drugs made by different manufacturers—to help address this issue.
However, a decade after its passage, the Biologics Price Competition and Innovation Act has spurred only limited competition.
